
Recent news
Stay up to date with recent updates on Social Impact group and our portfolio partners
Igyxos Initiates Phase 1 Clinical Trials for IGX12: A Breakthrough Treatment for Infertility
IGX12 is a pioneering monoclonal antibody (mAb) with very strong and consistent pre-clinical results and the potential to revolutionize infertility treatment.
Igyxos Announces Successful Closure of Second Largest Investment Round in its History, Marking a Milestone in its Growth
Financial proceeds will be used to advance Igyxos infertility breakthrough treatment towards its goal to transform lives of many facing fertility problems
Bloobloom eyewear to open five more London stores following new £5m investment
French designer eyewear brand Bloobloom, which was founded in 2018 and has stores on London’s Carnaby Street and Marylebone High Street, is to open five additional London stores in 2023, following a new £5m round of seed funding.
